Edgewise Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Edgewise Therapeutics, Inc. (EWTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.95 million shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2022-11-03
- Edgewise Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 2.61M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|
| 2022-09-30 | 2.61M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 2.95M shares 10-Q · filed 2022-11-03 | |
| 2022-06-30 | 335.25K shares 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |